Abstract
In a randomized prospective study ampicillin/sulbactam and cefamandole were compared in the therapy of patients hospitalized with community acquired pneumonia. Patients receiving ampicillin/sulbactam (n=37) and cefamandole (n=38) were similar with respect to age (mean age 70 vs. 76 years respectively), clinical characteristics, severity of illness and underlying disease. Pathogens isolated from patients in the cefamandole and ampicillin/sulbactam group, respectively, wereStreptococcus pneumoniae (7 vs. 7 patients),Haemophilus parainfluenzae (7 vs. 6 patients),Haemophilus influenzae (5 vs. 5 patients),Staphylococcus aureus (5 vs. 4 patients),Escherichia coli (4 vs. 4 patients),Klebsiella pneumoniae (3 vs. 3 patients),Enterobacter spp. (2 vs. 3 patients),Moraxella catarrhalis (1 vs. 2 patients), and organisms of the oral flora (4 vs. 3 patients). The rate of resistance to penicillin was 80 %, to clindamycin 76 %, to erythromycin 45 %, to ampicillin 43 %, and to cefazolin 18 %. Overall successful treatment rates of 81 % for cefamandole and 97 % for ampicillin/sulbactam (p=0.05) were observed. Both cefamandole and ampicillin/sulbactam were shown to be effective agents for therapy of community acquired pneumonia; however ampicillin/sulbactam demonstrated superior overall clinical efficacy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Donowitz GR, Mandell GL Empiric therapy for pneumonia. Reviews of Infectious Diseases 1983, Supplement 5: 40–51.
Lode H Initial therapy of pneumonia. American Journal of Medicine 1986, 80 Supplement 5C: 70–74.
Finch R, MacFarlane JT, Selkon JD, Watson J, White RJ, Winter JH, Woodhead MA Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. British Journal of Hospital Medicine 1993, 49: 346–50.
Berntsson E, Blomberg J, Lagergard T, Trollfors B Etiology of community-acquired pneumonia in patients requiring hospitalization. European Journal of Clinical Microbiology 1985, 4: 268–272.
Bently DW Bacterial pneumonia in the elderly: clinical features, diagnosis, etiology, and treatment. Gerontology 1984, 30: 297–307.
Berk SL, Wiener SL, Eisner LB, Duncan JW, Smith JK MixedStreptococcus pneumoniae and gram-negative bacillary pneumonia in the elderly. Southern Medical Journal 1981, 74: 144–146.
Dorff GJ, Rytel MW, Farmer SG, Scanlon G Etiologies and characteristic features of pneumonias in a municipal hospital. American Journal of the Medical Sciences 1973, 266: 349–358.
Ebright JR, Rytel MW Bacterial pneumonia in the elderly. Journal of American Geriatrics Society 1980, 28: 220–223.
Griffith DE Pneumonia in chronic lung disease. Infectious Disease Clinics of North America 1991, 5: 467–484.
Garb JL, Brown RB, Garb JR, Tuthill RW Differences in etiology of pneumonias in nursing homes and community patients. Journal of the American Medical Association 1978, 240: 2169–2172.
Garibalidi RA Epidemiology of community-acquired respiratory tract infections in adults. American Journal of Medicine 1985, 78 Supplement 6B: 32–37.
Karnad A, Salvador A, Berk SL Pneumonia caused by gram-negative bacilli. American Journal of Medicine 1985, 79 Supplement 1A: 61–67.
Klimek JJ, Ajemian E, Fontecchio S, Gracewski J, Klemas B, Jimenez L Community-acquired pneumonia requiring admission to hospital. American Journal of Infection Control 1983, 11: 79–82.
MacFarlane JT, Finch RG, Ward MJ, MacRae AD Hospital study of adult community-acquired pneumonia. Lancet 1982; ii: 255–258.
Sullivan RJ, Dowdle WB, Marine MW, Hierholzer JC Adult pneumonia in a general hospital. Archives of Internal Medicine 1972, 129: 935–942.
Verghese A, Berk S Bacterial pneumonia in the elderly. Medicine 1983, 62: 271–285.
White RJ, Blainey AD, Harrison KJ, Clark SKR Causes of pneumonia presenting to a district general hospital. Thorax 1982, 36: 566–570.
Murray PR, Washington JA Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clinic Proceedings 1975, 50: 339–344.
McCabe WR, Jackson GG Gram-negative bacteremia. I: Etiology and ecology. Archives of Internal Medicine 1962, 110: 847–855.
National Committee for Clinical Laboratory Standards Performance standards for clinical laboratory standards. Approved Standard M7-A2, NCCLS, Villanova, PA, 1990.
National Committee for Clinical Laboratory Standards Performance standards for microdilution susceptibility tests. Approved Standard M2-A4. NCCLS, Villanova, PA, 1990.
Rhind GB, Gould GA, Ahmad F, Croughan MJ, Calder MA Haemophilus parainfluenzae andHaemophilus influenzae respiratory infections: comparison of clinical features. British Medical Journal 1985, 291: 707–708.
Foweraker JE, Cooke NJ, Hawkey PM Ecology ofHaemophilus influenzae andHaemophilus parainfluenzae in sputum and saliva and effects of antibiotics or their distribution in patients with lower respiratory tract infection. Antimicrobial Agents and Chemotherapy 1993, 37: 804–809.
Fekety FR, Caldwell J, Gump D, Johnson JE, Maxson W, Mulholland J, Thoburn R Bacteria, viruses, and mycoplasmas in acute pneumonia in adults. American Review Respiratory Disease 1971, 104: 499–507.
Fiala M A study of the combined role of viruses, mycoplasmas in acute pneumonia in adults. American Journal of Medicine Science 1969, 257: 44–51.
Larsen RA, Jacobson JA Diagnosis of community-acquired pneumonia: experience of a community hospital. Comprehensive Therapy 1984, 10: 20–25.
Karalus NC, Cursons RT, Leng RA, Mahood CB, Rothwell RPG, Hancock B, Cepulis S, Wawatai M, Coleman L Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991, 46: 413–418.
Fang GD, Fine MJ, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee YC, Rihs JD, Vickers RM New and emerging etiologies for community acquired pneumonia with implications for therapy. Medicine 1990, 69: 307–316.
Farr BM, Sloman AJ, Fisch MJ Predicting death in patients hospitalized for community-acquired pneumonia. Annals of Internal Medicine 1991, 115: 428–436.
Engle JC, Lifland PW, Schleupner CJ Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia. Antimicrobial Agents and Chemotherapy 1985, 28: 146–148.
Wallace RJ, Niefield SL, Waters S, Waters B, Awe RJ, Wiss K, Martin RR, Greenberg SB Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrobial Agents Chemotherapy 1982, 21: 231–235.
Weber DJ, Calderwood SB, Karchner AW, Pennington JE Ampicillin versus cefamandole as initial therapy for community acquired pneumonia. Antimicrobial Agents Chemotherapy 1987, 31: 876–882.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Williams, D., Perri, M. & Zervos, M.J. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 13, 293–298 (1994). https://doi.org/10.1007/BF01974603
Issue Date:
DOI: https://doi.org/10.1007/BF01974603